Ovarian cancer, from the laboratory to the clinic: Challenges for the future. ESMO-Award lecture, ECCO-8 Paris, 28 October - 2 November 1995

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 9-13

  Kaye, S B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Challenges; Clinic; Laboratory; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ALOPECIA; BONE MARROW SUPPRESSION; FEMALE; HUMAN; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL;

CLINICAL TRIALS; FEMALE; FORECASTING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RESEARCH;

EID: 0030061624     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010488     Document Type: Article

References (26)

1. Beral V. The epidemiology of ovarian cancer. In Sharp F, Soutter WP (eds): Ovarian Cancer, the Way Ahead. London: Royal College of Obst Gynec 1987; 21-32.
2. Gillis CR, Hole DJ, Still RM et al. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 1991; 337: 611-2.
3. Behrens BC, Hamilton TC, Masuda H et al. Characterization of a cisplatin-resistant human ovarian cancer cell line and its use in the evaluation of platinum analogues. Cancer Res 1987; 47:414-8.
4. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: Perspectives on mechanisms of required resistance. Cancer Cells 1990; 2: 35-43.
5. O'Dwyer PJ, Hamilton TC, Young RC et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine. J Natl Cancer Inst 1992; 84: 264-7.
6. Masuda H, Ozols RF, Lai G-M et al. Increased DNA repair as a mechanism of acquired resistance to cM-Diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988; 48: 5713-6.
7. Kaye SB,. P-glycoprotein (P-gp) and drug resistance - time for reappraisal? Br J Cancer 1993; 67: 641-3.
8. Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug resistant cells by the cyclosporin SDZ PSC 833 and the cyclopeptide SDZ 280-446. J Natl Cancer Inst 1993; 85: 478-83.
9. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of cisplatin resistance in human ovarian cancer cell lines derived from tumors of untreated patients and patients treated with platinum-based chemotherapy. Int J Gynacol Cancer 1995; 5 (Suppl 1): 40.
10. Brown R, Clugston C, Burns P et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993; 55: 678-84.
11. Anthoney A, Brown R. The detection of genomic instability in drug resistant human tumour cell lines. Proc Am Assoc Cancer Res 1995; 36: 323.
12. Vasey PA, Jenkins S, Bissett D, Brown R. p53-mediated multiagent resistance, and approaches to circumvention in a human ovarian cell line. Br J Cancer 1995; 71 (Suppl 24): 7.
13. Murphy D, McGown AT, Hall A et al. Glutathione-S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 1992; 66: 937-42.
14. Van der Zee AG, Hollema H, Swurmeier AJ et al. The value of P-glycoprotein, glutathione-S-transferase, C-erbB-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
15. Izquierdo MA, van der Zee A, Vermorken J et al. Prognostic significance of the drug resistance associated protein LRP in advanced ovarian carcinoma. Ann Oncol 1994; 5: 98.
16. Al-Azraqui A, Chapman C, Challen C et al. p53 alterations in ovarian cancer as a determinant of response to carboplatin. Br J Cancer 1994; 69: 7.
17. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-67.
18. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 1995; 13: 1589-99.
19. Kaye SB, Lewis CR, Paul J et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
20. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol; in press.
21. Alberts DS, Liu PY, Hannigan EV et al. Phase III study of intraperitoneal cisplatin/intravenous cyclophosphamide versus IV cisplatin/TV cyclophosphamide in patients with optimal stage III ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 273.
22. Kaye SB. Taxoids. Eur J Cancer 1995; 31A: 824-6.
23. McGuire W, Hoskins W, Brady M et al. Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 1995; 14: 275.
24. Armstrong D, Rowinsky E, Donehower R et al. Phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275.
25. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: Referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363-70.
26. Van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-34.